Armata Pharmaceuticals, Inc. (ARMP)
USD 1.95
(-2.5%)
USD 1.95
(-2.5%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -29.24 Million USD | -733.47% |
| 2022 | 4.61 Million USD | 129.7% |
| 2021 | -15.54 Million USD | -14.1% |
| 2020 | -13.62 Million USD | -908.22% |
| 2019 | -1.35 Million USD | 0.0% |
| 2018 | -1.35 Million USD | -421.62% |
| 2017 | -259 Thousand USD | -137.61% |
| 2016 | -109 Thousand USD | -122.95% |
| 2015 | 475 Thousand USD | 16.14% |
| 2014 | 409 Thousand USD | 25.85% |
| 2013 | 325 Thousand USD | -51.05% |
| 2012 | 664 Thousand USD | 0.0% |
| 2008 | 8.71 Million USD | -15.62% |
| 2007 | 10.33 Million USD | 4.74% |
| 2006 | 9.86 Million USD | 43.5% |
| 2005 | 6.87 Million USD | -28.78% |
| 2004 | 9.65 Million USD | -31.41% |
| 2003 | 14.07 Million USD | -27.21% |
| 2002 | 19.33 Million USD | 2.4% |
| 2001 | 18.88 Million USD | 43.28% |
| 2000 | 13.17 Million USD | 56.87% |
| 1999 | 8.4 Million USD | -4.55% |
| 1998 | 8.8 Million USD | 252.0% |
| 1997 | 2.5 Million USD | -40.48% |
| 1996 | 4.2 Million USD | 180.0% |
| 1995 | 1.5 Million USD | -11.76% |
| 1994 | 1.7 Million USD | 240.0% |
| 1993 | 500 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 649 Thousand USD | -47.45% |
| 2024 Q2 | -315 Thousand USD | -148.54% |
| 2023 FY | 3.55 Million USD | -22.94% |
| 2023 Q1 | 566 Thousand USD | -29.78% |
| 2023 Q2 | 780 Thousand USD | 37.81% |
| 2023 Q4 | 1.23 Million USD | 23.01% |
| 2023 Q3 | 1 Million USD | 28.72% |
| 2022 Q2 | 1.68 Million USD | 0.0% |
| 2022 FY | 4.61 Million USD | 129.7% |
| 2022 Q1 | - USD | 0.0% |
| 2022 Q4 | 806 Thousand USD | -27.52% |
| 2022 Q3 | 1.11 Million USD | -34.12% |
| 2021 Q3 | - USD | 0.0% |
| 2021 Q4 | - USD | 0.0% |
| 2021 Q1 | 1.06 Million USD | 3538.71% |
| 2021 Q2 | - USD | -100.0% |
| 2021 FY | -15.54 Million USD | -14.1% |
| 2020 Q2 | 31 Thousand USD | 0.0% |
| 2020 Q3 | - USD | -100.0% |
| 2020 Q4 | -31 Thousand USD | 0.0% |
| 2020 FY | -13.62 Million USD | -908.22% |
| 2020 Q1 | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 FY | -1.35 Million USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 FY | -1.35 Million USD | -421.62% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q1 | - USD | -100.0% |
| 2017 Q2 | 28 Thousand USD | -3.45% |
| 2017 Q4 | 20 Thousand USD | -47.37% |
| 2017 Q1 | 29 Thousand USD | 31.82% |
| 2017 FY | -259 Thousand USD | -137.61% |
| 2017 Q3 | 38 Thousand USD | 35.71% |
| 2016 Q1 | 106 Thousand USD | -17.19% |
| 2016 FY | -109 Thousand USD | -122.95% |
| 2016 Q3 | 29 Thousand USD | -71.84% |
| 2016 Q4 | 22 Thousand USD | -24.14% |
| 2016 Q2 | 103 Thousand USD | -2.83% |
| 2015 Q3 | 143 Thousand USD | 40.2% |
| 2015 Q2 | 102 Thousand USD | 0.0% |
| 2015 Q1 | 102 Thousand USD | 3.03% |
| 2015 FY | 475 Thousand USD | 16.14% |
| 2015 Q4 | 128 Thousand USD | -10.49% |
| 2014 Q2 | 310 Thousand USD | -99.7% |
| 2014 Q3 | 103 Million USD | 33125.81% |
| 2014 Q4 | 99 Thousand USD | -99.9% |
| 2014 FY | 409 Thousand USD | 25.85% |
| 2014 Q1 | 104 Million USD | 1300100.0% |
| 2013 Q3 | -3000.00 USD | -100.96% |
| 2013 Q4 | -8000.00 USD | -166.67% |
| 2013 Q2 | 314 Thousand USD | 1327.27% |
| 2013 Q1 | 22 Thousand USD | 0.0% |
| 2013 FY | 325 Thousand USD | -51.05% |
| 2012 FY | 664 Thousand USD | 0.0% |
| 2009 Q1 | 2.02 Million USD | -9.78% |
| 2009 Q2 | 3.36 Million USD | 66.35% |
| 2009 Q3 | 3.71 Million USD | 10.38% |
| 2008 Q3 | 1.74 Million USD | -22.13% |
| 2008 FY | 8.71 Million USD | -15.62% |
| 2008 Q4 | 2.24 Million USD | 28.59% |
| 2008 Q1 | 2.49 Million USD | -22.39% |
| 2008 Q2 | 2.23 Million USD | -10.48% |
| 2007 Q1 | 1.66 Million USD | -58.56% |
| 2007 Q2 | 3 Million USD | 81.1% |
| 2007 Q3 | 2.44 Million USD | -18.78% |
| 2007 Q4 | 3.22 Million USD | 31.81% |
| 2007 FY | 10.33 Million USD | 4.74% |
| 2006 Q1 | 2.43 Million USD | 25.0% |
| 2006 Q2 | 1.41 Million USD | -41.81% |
| 2006 Q4 | 4 Million USD | 99.2% |
| 2006 Q3 | 2.01 Million USD | 42.29% |
| 2006 FY | 9.86 Million USD | 43.5% |
| 2005 Q2 | 1.46 Million USD | -26.9% |
| 2005 FY | 6.87 Million USD | -28.78% |
| 2005 Q3 | 1.46 Million USD | 0.41% |
| 2005 Q1 | 2 Million USD | -37.17% |
| 2005 Q4 | 1.94 Million USD | 32.43% |
| 2004 Q3 | 2.38 Million USD | -13.51% |
| 2004 Q4 | 3.18 Million USD | 33.29% |
| 2004 Q1 | 1.32 Million USD | -4.28% |
| 2004 Q2 | 2.76 Million USD | 109.17% |
| 2004 FY | 9.65 Million USD | -31.41% |
| 2003 Q2 | 2.05 Million USD | -63.59% |
| 2003 Q4 | 1.37 Million USD | -72.43% |
| 2003 FY | 14.07 Million USD | -27.21% |
| 2003 Q1 | 5.63 Million USD | 23.99% |
| 2003 Q3 | 5 Million USD | 143.64% |
| 2002 FY | 19.33 Million USD | 2.4% |
| 2002 Q1 | 5.37 Million USD | 3.31% |
| 2002 Q2 | 4.59 Million USD | -14.47% |
| 2002 Q3 | 4.82 Million USD | 4.99% |
| 2002 Q4 | 4.54 Million USD | -5.68% |
| 2001 Q3 | 5.53 Million USD | 27.65% |
| 2001 Q4 | 5.19 Million USD | -6.15% |
| 2001 Q2 | 4.33 Million USD | 14.01% |
| 2001 Q1 | 3.8 Million USD | 118.45% |
| 2001 FY | 18.88 Million USD | 43.28% |
| 2000 Q3 | 6.77 Million USD | 218.16% |
| 2000 FY | 13.17 Million USD | 56.87% |
| 2000 Q4 | 1.74 Million USD | -74.3% |
| 2000 Q2 | 2.13 Million USD | -15.73% |
| 2000 Q1 | 2.52 Million USD | -23.4% |
| 1999 FY | 8.4 Million USD | -4.55% |
| 1999 Q1 | 1.7 Million USD | -77.33% |
| 1999 Q2 | 1.8 Million USD | 5.88% |
| 1999 Q3 | 1.8 Million USD | 0.0% |
| 1999 Q4 | 3.3 Million USD | 83.33% |
| 1998 Q2 | 700 Thousand USD | 0.0% |
| 1998 Q4 | 7.5 Million USD | 1150.0% |
| 1998 Q3 | 600 Thousand USD | -14.29% |
| 1998 Q1 | 700 Thousand USD | 600.0% |
| 1998 FY | 8.8 Million USD | 252.0% |
| 1997 Q3 | 800 Thousand USD | 166.67% |
| 1997 Q1 | 400 Thousand USD | -73.33% |
| 1997 FY | 2.5 Million USD | -40.48% |
| 1997 Q4 | 100 Thousand USD | -87.5% |
| 1997 Q2 | 300 Thousand USD | -25.0% |
| 1996 FY | 4.2 Million USD | 180.0% |
| 1996 Q4 | 1.5 Million USD | 87.5% |
| 1996 Q3 | 800 Thousand USD | 700.0% |
| 1996 Q1 | 200 Thousand USD | 0.0% |
| 1996 Q2 | 100 Thousand USD | -50.0% |
| 1995 Q3 | 100 Thousand USD | 0.0% |
| 1995 Q4 | - USD | -100.0% |
| 1995 FY | 1.5 Million USD | -11.76% |
| 1995 Q1 | 100 Thousand USD | 0.0% |
| 1995 Q2 | 100 Thousand USD | 0.0% |
| 1994 Q4 | 100 Thousand USD | -50.0% |
| 1994 FY | 1.7 Million USD | 240.0% |
| 1994 Q1 | 100 Thousand USD | 0.0% |
| 1994 Q2 | 100 Thousand USD | 0.0% |
| 1994 Q3 | 200 Thousand USD | 100.0% |
| 1993 Q4 | - USD | -100.0% |
| 1993 Q1 | 100 Thousand USD | 0.0% |
| 1993 FY | 500 Thousand USD | 0.0% |
| 1993 Q3 | 100 Thousand USD | 0.0% |
| 1993 Q2 | 100 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 160 Thousand USD | 18375.625% |
| Ampio Pharmaceuticals, Inc. | -250 Thousand USD | -11596.4% |
| Actinium Pharmaceuticals, Inc. | -709 Thousand USD | -4024.26% |
| Azitra, Inc. | 260.45 Thousand USD | 11327.064% |
| Can-Fite BioPharma Ltd. | 743 Thousand USD | 4035.532% |
| Chromocell Therapeutics Corporation | -2.57 Million USD | -1033.628% |
| Calidi Biotherapeutics, Inc. | -1.25 Million USD | -2228.105% |
| CEL-SCI Corporation | -3.95 Million USD | -638.72% |
| iBio, Inc. | -1.02 Million USD | -2752.78% |
| Lineage Cell Therapeutics, Inc. | 8.27 Million USD | 453.408% |
| MAIA Biotechnology, Inc. | - USD | Infinity% |
| Matinas BioPharma Holdings, Inc. | -13.39 Million USD | -118.33% |
| Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | -24411.505% |
| NovaBay Pharmaceuticals, Inc. | 7.89 Million USD | 470.374% |
| NanoViricides, Inc. | -759.01 Thousand USD | -3752.498% |
| Oragenics, Inc. | -15.45 Million USD | -89.226% |
| BiomX Inc. | -1.22 Million USD | -2281.189% |
| BiomX Inc. | -1.22 Million USD | -2281.189% |
| Protalix BioTherapeutics, Inc. | 42.51 Million USD | 168.783% |
| Palatin Technologies, Inc. | 4.39 Million USD | 765.71% |
| Scorpius Holdings, Inc. | -2.21 Million USD | -1219.292% |